InnoCare Pharma (OTCMKTS:INCPF – Get Free Report) is expected to be issuing its resultson Monday, October 26th. Analysts expect InnoCare Pharma to post earnings of ($0.0385) per share and revenue of $23.00 million for the quarter.
InnoCare Pharma Price Performance
Shares of InnoCare Pharma stock opened at $1.60 on Friday. InnoCare Pharma has a 1-year low of $1.60 and a 1-year high of $1.85. The firm’s 50-day moving average price is $1.62 and its two-hundred day moving average price is $1.57.
InnoCare Pharma Company Profile
InnoCare Pharma Limited is a biopharmaceutical company focused on discovering, developing and commercializing innovative medicines for cancer and autoimmune diseases. The company conducts research in areas including targeted therapies, immuno-oncology and treatments designed to address significant unmet medical needs.
Its primary commercial product is orelabrutinib, a highly selective Bruton’s tyrosine kinase inhibitor marketed in China for certain B-cell malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia or small lymphocytic lymphoma.
Featured Stories
- Five stocks we like better than InnoCare Pharma
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for InnoCare Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnoCare Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
